Pediatric Phase I Trial and Pharmacokinetic Study of Vorinostat: A Children's Oncology Group Phase I Consortium Report

PURPOSE: The purpose of this study was to determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of vorinostat administered as a single agent and in combination 13-cis retinoic acid (13cRA) in children with refractory solid tumors; to evaluate the tolerabili...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Fouladi, Maryam, Park, Julie R., Stewart, Clinton F., Gilbertson, Richard J., Schaiquevich, Paula, Sun, Junfeng, Reid, Joel M., Ames, Matthew M., Speights, Roseanne, Ingle, Ashish M., Zwiebel, James, Blaney, Susan M., Adamson, Peter C.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2010
Teme:
Original Reports
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2917318/
https://ncbi.nlm.nih.gov/pubmed/20606092
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.25.9119
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki